HNGE HNGE
Company Profile ↓Company Overview
HNGE (HNGE) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 41.7% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $587.86M (+50.6% YoY); net profit $-528.26M.
- Trailing 12 Months Year-on-year growth — revenue +50.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 41.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 41.71% |
| 1 Year: | 50.58% |
Stock Price Performance
| 1 Year: | +67.54% |
| 6 Months: | +144.30% |
| 3 Months: | +62.39% |
| 1 Month: | -9.53% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)55.97 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 41.7% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 89.83M | 100.61M | 123.83M | 139.10M | 154.21M | 182.31M |
| Gross Profit | - | 66.62M | 79.26M | 100.23M | 97.76M | 126.20M | 154.23M |
| Operating Income | - | -17.55M | -3.85M | 13.14M | -580.67M | -6.09M | 32.07M |
| Net Income | -26.46M | -12.93M | 341.00K | 17.14M | -575.65M | -1.84M | 35.13M |
| Diluted EPS | - | -0.96 | 0.01 | 1.31 | -13.10 | -0.02 | 0.41 |
| R&D Expense | - | 24.92M | 23.79M | 23.50M | 279.96M | 31.92M | 30.34M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 292.73M | 390.40M | 587.86M |
| Gross Profit | 194.18M | 299.90M | 468.22M |
| Operating Income | -130.51M | -31.91M | -546.37M |
| Net Income | -108.14M | -11.93M | -528.26M |
| Diluted EPS | -8.31 | -0.88 | -7.77 |
| R&D Expense | 110.06M | 100.84M | 368.14M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | - | 673.26M | 744.76M |
| Total Equity | -318.12M | -423.99M | -434.57M | 178.66M |
| Cash & Equivalents | - | 234.95M | 300.79M | 208.00M |
| Total Liabilities | - | - | 256.56M | 366.23M |
| Current Liabilities | - | - | 249.30M | 362.41M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -63.91M | 49.00M | 171.44M |
| Investing Cash Flow | 1.50M | 18.31M | -113.76M |
| Financing Cash Flow | -3.00M | -2.20M | -150.47M |
| Capital Expenditure | -4.62M | -3.77M | -6.06M |
| Free Cash Flow | -68.52M | 45.23M | 165.38M |
| Net Change in Cash | -65.41M | 65.11M | -92.79M |
| Share Buybacks | 0 | 0 | 65.03M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | 66.3% | 76.8% | 79.6% |
| Operating Margin % | -44.6% | -8.2% | -92.9% |
| Net Margin % | -36.9% | -3.1% | -89.9% |
| ROE % | 25.5% | 2.7% | -295.7% |
| ROCE % | - | -7.5% | -142.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HNGE
HNGE Q2 Earnings Meet Estimates, Sales Top, '26 View Raised, Stock Up - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPYVowdFhxWkZXWUJSLWhIajVXN3pVQmN0VEl3OUdWeFRNbW1fQlIzbHlwbTZ4azY1dzdvUXNuY3JBRVlJeDBENVV1UzBmX3JiSXFSdks4eWlJN3RiWUpfUDFTdDFKXzF0bVBCTmptMFRUc3FJYWNtSE5mTjBUeDZPYlJMZWpid0RTVWlBV0…
Citizens Jmp Issues Positive Forecast for Hinge Health (NYSE:HNGE) Stock Price - MarketBeat
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxOc29QRHhtMGRfOVVRaTJUUXplUUtvaVBYT1JEOV8weHAyT2ZLSDlxNHdFa0NTbXYyMHYxNlpPcXB2Z2tsZzVNTGtNZk1IWDZaRS1XSEp1NElLalZVN1RZdTNxZ1RXci1hS3g1ZjRqakR2R01CMG9jTGJ1akJqa0ZHMTdUZHprRFdFaHdMbF…
Citizens raises Hinge Health stock price target on GI expansion, results - Investing.com
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxOOC1QTVhabGpUUlp2Q2ZwSXJ5SDBMeDV5TUJrbGN1Qkp6NEdQOENpLVp5V3dqamI5b25UQnAzUXRyX3E4dlIyTTFTTnRIUHlFSVZLSXBhRmYzeFYxS1pPdVVzTXRBYTYzbXhma0dVeGZPYS1HRGtUamNLbHFMLTJsYUcyMkZDWng0b2Zlbm…
Hinge Health, Inc. Stock 12‑Month Price Target Raised to $101.67, Implies 28% Upside - TradingView
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxNUlprRHNTd1N6UzdtajdiekJ1eE1kZkZ2X2dfcF9nOHJZN1NEZmFSSm1HMFhuVDMzcEo5OUsxRnhGS3Z1ZHZfYlFHdXIyV3lnSFNOMmdKUFIyamxoYUNSYUctYjY3UUp2TnNDYVBDUG9MNm8tYzE2ZElUUmdaa0xBc2hRYlhkckRiZ2tfYW…
Hinge Health (HNGE) Is Up 5.5% After Raising 2026 Outlook And Announcing Cylinder Deal - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPTVRDV2VEclJXYkVyc1lfVk9lZ2pKc2xsSXBreVF5S1pCV1d1TExXU2NFOXM3ZjZ0RHdaTURzb0JZQ01GVnZzY05zeUFSOE5tMHhycWdzZkRNaFhaVGRxRXZGb01ZRkw2S1ZrQkxrQTV2RWg1dlZQbXIwNFdmN2V2WGx3V1l1ckEwZ1BQRX…
Hinge Health plans GI care in one app; 69% of counties lack gastroenterologists - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxNMm9YOGprRWhCcUwtbjNDMUc0SzZlMnhDZlRqWEtmcVJjNVVQd2twREhKN1VTT0xtNmZDX1U0UXJqRElRVi1pTVdHWFVwRGdzTEZ3QkVkaGFXaXRVSkc4c0tjXzZkZmFiMXhJeUNwMXA3TkFaaXlrSHpBTjNEYlBTRUhXd2Q4YndXR3N1ZD…
HNGE — Frequently Asked Questions
What is the current share price of HNGE?
As of 2026-08-05 17:25 PDT, HNGE trades at $80.79 on NASDAQ/NYSE. Its 52-week range is $31.17 to $90.00.
What is the P/E ratio of HNGE?
HNGE trades at a trailing price-to-earnings (P/E) ratio of -10.40.
Is HNGE a good stock to buy?
This page provides a data-driven analysis of HNGE, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.